Compare Aurora Cannabis Inc (ACB) vs Expensify Inc (EXFY) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Expensify (EXFY) trades at $1.71, up 0.59% with a bullish technical signal from moving averages. The company maintains strong revenue around $142M but continues to report net losses, with a negative net income margin of -14.68%. Recent developments include AI product expansions and a $25M stock buyback program. Analyst sentiment is mixed with a 44% buy rating, while technical indicators show RSI levels suggesting potential overbought conditions near-term.

The outlook remains challenging with persistent profitability issues despite stable revenue. Investment opportunity exists in the company's AI initiatives and market positioning, but risks include ongoing losses, competitive pressure, and execution challenges. The stock's high P/E ratio of 258.82 reflects growth expectations that must materialize to justify current valuation levels.